Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 03

397P - Efficacy and safety of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive or HER2-low expressing, locally advanced or metastatic breast cancer: A single-arm phase II study

Date

21 Oct 2023

Session

Poster session 03

Topics

Tumour Site

Breast Cancer

Presenters

Fei Qu

Citation

Annals of Oncology (2023) 34 (suppl_2): S334-S390. 10.1016/S0923-7534(23)01260-7

Authors

F. Qu1, W. Li2, Y. yin2

Author affiliations

  • 1 Oncology, Jiangsu Province Hospital/The First Affiliated Hospital of Nanjing Medical University, 210029 - Nanjing/CN
  • 2 Oncology Department, Jiangsu Province Hospital - The First Affiliated Hospital with Nanjing Medical University, 210029 - Nanjing/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 397P

Background

Current treatment options for HER2-positive (IHC 3+, or IHC 2+/FISH+) metastatic breast cancer (MBC) at third-line and above have shown limited clinical benefit. There is no recommended HER2-targeting treatment for HER2-low expressing (IHC 2+/FISH-, or IHC 1+) population. Here, we report the efficacy and safety of RC48-ADC in patients with MBC.

Methods

Patients with HER2-positive or HER2-low expressing MBC were eligible and received RC48 2.5 mg/kg every two weeks alone or combined with drugs with different anti-tumor mechanisms, such as immune checkpoint inhibitors (ICIs), tyrosine kinase inhibitors (TKIs) and antiangiogenic compounds. The primary endpoint was the objective response rate (ORR). Secondary endpoints included progression-free survival (PFS), overall survival (OS), disease control rate (DCR) and safety.

Results

76 female MBC patients were enrolled and treated with RC48. 58 patients (76.3%) were HER2-positive and 18 patients (23.7%) were HER2-low expressing. At baseline, 35 patients (46.0%) had liver metastases, 27 patients (35.5%) had brain metastases, and 67 patients (88.1%) had received ≥3 prior chemotherapy regimens. In the overall population, the ORR was 31.6%. The median PFS was 5.7 months. The DCR was 57.9%. In the HER2-positive subgroup, the ORR and mPFS were 34.5% and 6.3 months. In the HER2-low expressing subgroup, the ORR and mPFS were 22.2% and 3.6 months. In addition, the mPFS in the dual drug combination-treated group was longer than that in the single drug treatment group, with mPFS of 7.1 months and 4.6 months, respectively. The most frequently reported adverse events were increased AST (62.4%), increased ALT (61.9%), decreased white blood cell count (42.4%), and fatigue (30.4%), most were grade 1-2 in severity.

Conclusions

RC48-ADC showed consistent efficacy in HER2-positive and HER2-low expressing subgroups. No new safety signals were observed. Coadministration with ICIs, TKIs and antiangiogenic compounds demonstrated substantially enhanced efficacy and could be a future direction of ADC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.

  • Analytics cookies help us improve our website by collecting and reporting information on its usage.

  • We use marketing cookies to build a profile of you as a user through your actions on our site in order to better understand your interests and provide you with pertinent suggestions.